ReviewAmerican health & drug benefits2012
Conceptual and Analytical Considerations toward the Use of Patient-Reported Outcomes in Personalized Medicine.
Review in American health & drug benefits, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genetic profile and patient-reported outcomes in chronic obstructive pulmonary disease: A systematic review.PloS one · 2018Pooled it
- When patient-reported respiratory symptoms shed light on pathophysiology in adult asthma: a cross-sectional study.Scientific reports · 2024Article
- Airways Type-2 Related Disorders: Multiorgan, Systemic or Syndemic Disease?International journal of molecular sciences · 2024Review
- The role of health-related quality of life in improving cancer outcomes.Journal of clinical and translational research · 2023Article
- Care for Patients with Type-2 Chronic Rhinosinusitis.Journal of personalized medicine · 2023Article
- Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational study.Health and quality of life outcomes · 2021Observational
- Integration of patient-reported outcomes (PROs) for personalized symptom management in "real-world" oncology practices: a population-based cohort comparison study of impact on healthcare utilization.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Observational
- Personalized symptom management: a quality improvement collaborative for implementation of patient reported outcomes (PROs) in 'real-world' oncology multisite practices.Journal of patient-reported outcomes · 2020Article
- Depressive Symptom Trajectories Among People Living with HIV in a Collaborative Care Program.AIDS and behavior · 2020Article
- Heterogeneous depression trajectories in multiple sclerosis patients.Multiple sclerosis and related disorders · 2016Article
- A tutorial on structural equation modeling for analysis of overlapping symptoms in co-occurring conditions using MPlus.Statistics in medicine · 2015Article
- Disentangling Multiple Sclerosis and depression: an adjusted depression screening score for patient-centered care.Journal of behavioral medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatient-reported outcomes (PROs) can play an important role in personalized medicine. PROs can be viewed as an important fundamental tool to measure the extent of disease and the effect of treatment at the individual level, because they reflect the self-reported health state of the patient directly. However, their effective integration in personalized medicine requires addressing certain conceptual and methodological challenges, including instrument development and analytical issues.
objectivesTo evaluate methodological issues, such as multiple comparisons, missing data, and modeling approaches, associated with the analysis of data related to PRO and personalized medicine to further our understanding on the role of PRO data in personalized medicine. DISCUSSION: There is a growing recognition of the role of PROs in medical research, but their potential use in customizing healthcare is not widely appreciated. Emerging insights into the genetic basis of PROs could potentially lead to new pathways that may improve patient care. Knowledge of the biologic pathways through which the various genetic predispositions propel people toward negative or away from positive health experiences may ultimately transform healthcare. Understanding and addressing the conceptual and methodological issues in PROs and personalized medicine are expected to enhance the emerging area of personalized medicine and to improve patient care. This article addresses relevant concerns that need to be considered for effective integration of PROs in personalized medicine, with particular reference to conceptual and analytical issues that routinely arise with personalized medicine and PRO data. Some of these issues, including multiplicity problems, handling of missing values-and modeling approaches, are common to both areas. It is hoped that this article will help to stimulate further research to advance our understanding of the role of PRO data in personalized medicine.
conclusionA robust conceptual framework to incorporate PROs into personalized medicine can provide fertile opportunity to bring these two areas even closer and to enhance the way a specific treatment is attuned and delivered to address patient care and patient needs.
Identifiers
24991329PMC4046457What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.